Medicare GLP-1 coverage in 2026: the $50 Bridge program explained
For the first time in 20+ years, Medicare covers weight-loss drugs. What the July 2026 Bridge program covers, who qualifies, and the catches that matter.
Medicare's historic shift on weight-loss drugs
For more than two decades, federal law barred Medicare from covering medications taken solely for weight loss — a ban dating to the 2003 law that created Part D. That changed on July 1, 2026, when the Centers for Medicare & Medicaid Services launched the Medicare GLP-1 Bridge, a temporary pilot that lets eligible Part D enrollees get certain weight-loss GLP-1s for a flat $50 monthly copay. It's a significant development given that more than a third of Medicare beneficiaries have obesity, and many had faced cash prices exceeding $1,000 per month.
What the Bridge covers — and what it doesn't
The program covers specific FDA-approved weight-loss formulations: Wegovy (both the injection and the new pill), Zepbound KwikPen, and Foundayo. It does not cover single-dose Zepbound vials or pens, and it does not cover compounded GLP-1s. A standout feature is the flat copay: the $50 stays the same whether you're on a low starting dose or a high maintenance dose, which is unusual and valuable because most people need higher doses over time.
Who qualifies
Eligibility centers on being actively enrolled in a Part D plan or a Medicare Advantage plan with drug coverage, being 18 or older, meeting the clinical criteria (a qualifying BMI at the time GLP-1 therapy started), and completing a prior authorization in which your prescriber certifies you're using the drug alongside a diet-and-exercise program. Notably, people who already get a GLP-1 through their Part D plan — for example for type 2 diabetes, cardiovascular disease, or sleep apnea — generally aren't eligible for the Bridge, because they already have a coverage path.
| Feature | Medicare GLP-1 Bridge |
|---|---|
| Start / end | July 1, 2026 – December 31, 2027 |
| Copay | $50/month flat (all doses) |
| Covered drugs | Wegovy (pill + injection), Zepbound KwikPen, Foundayo |
| Requires | Part D enrollment, prior authorization, clinical criteria |
| Counts toward Part D cap? | No |
The catches worth knowing
Three caveats matter. First, the $50 copay does not count toward the Part D annual out-of-pocket cap ($2,100 in 2026), because the Bridge runs alongside Part D rather than through it. Second, it's temporary — scheduled to end December 31, 2027, with a longer-term program (the BALANCE Model) expected to follow, meaning you may need to choose a participating plan during open enrollment to keep coverage. Third, it excludes compounded GLP-1s entirely, so if you're on a compounded program you'd need to switch to a covered brand product to use the benefit.
Bridge vs cash-pay compounded: which is cheaper?
For an eligible Medicare beneficiary, $50/month for an FDA-approved brand drug is hard to beat — it undercuts even the cheapest transparent cash-pay compounded programs and gives you the approved product. If you're eligible, the Bridge is very likely your lowest-cost, highest-assurance path, and worth pursuing first. If you're not eligible — because you're under 65 and not on Medicare, or you already have a Part D coverage path, or you don't meet the clinical criteria — then cash-pay options remain relevant, and a transparent flat-rate program is the predictable choice. Check eligibility with your provider before assuming either way; the paperwork is quick and the savings are large.
Frequently asked questions
Does Medicare cover weight-loss drugs in 2026?
Yes, for the first time. Starting July 1, 2026, the Medicare GLP-1 Bridge program covers Wegovy (pill and injection), Zepbound KwikPen, and Foundayo at a flat $50/month copay for eligible Part D enrollees, after a 20-plus-year federal ban on covering drugs solely for weight loss.
How much do GLP-1 drugs cost on Medicare now?
Eligible beneficiaries pay a flat $50/month copay through the GLP-1 Bridge, the same at any dose. Without the program, brand cash prices typically range from about $149 to $699/month depending on drug and dose.
Who is eligible for the Medicare GLP-1 Bridge?
Adults 18+ actively enrolled in a Part D plan or Medicare Advantage with drug coverage, who meet the clinical BMI criteria and complete a prior authorization. People already getting a GLP-1 through Part D (for diabetes, cardiovascular disease, or sleep apnea) generally aren't eligible for the Bridge.
Does the Medicare GLP-1 Bridge cover compounded semaglutide?
No. The Bridge covers only specific FDA-approved brand formulations (Wegovy, Zepbound KwikPen, Foundayo). Compounded GLP-1s are not covered.
When does the Medicare GLP-1 Bridge end?
It's scheduled to run from July 1, 2026 through December 31, 2027, with a longer-term program (the BALANCE Model) expected to follow. You may need to choose a participating plan during open enrollment to keep coverage afterward.
References
- CMS / Medicare.gov. Weight loss drugs coverage — Medicare GLP-1 Bridge, 2026.
- Humana. Does Medicare cover GLP-1 weight loss drugs, 2026.
- NPR. Medicare launches weight-loss drug option with $50 copay, May 2026.
- CNN. Medicare to start covering weight-loss drugs July 1, June 2026.
Clinical and regulatory figures from published trials, FDA, and CMS communications; pricing from provider-advertised and manufacturer rates checked July 2026 and subject to change. Educational, not medical or financial advice.